Manufacturer
ABBVIE S.R.L.
Contents
Palivizumab
Indication
Synagis 50 mg and 100 mg for injection, is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients :- Whom with a history of premature birth (≤35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season.Secondly patient with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season and lastly patient with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season
Instruction
Synagis is given as a monthly injection, usually in the thigh (leg) muscle, by your child’s healthcare provider. Intramuscular: Passive immunisation of infants against lower respiratory tract infections
Child: <2 yr 15 mg/kg mthly during the season of resp syncytial virus (RSV) risk. Subsequent doses should be given mthly until the end of the season. Undergone cardiac bypass surgery: 15 mg/kg as soon as stable post-op. Admin preferably in the anterolateral thigh; vol >1 mL should be given in divided doses.
Drug interaction
No formal drug-drug interaction studies were conducted. In Trial 1, the proportions of children in the placebo and Synagis groups who received routine childhood vaccines, influenza vaccine,bronchodilators, or corticosteroids were similar and no incremental increase in adverse reactions was observed among children receiving these agents.
Malaysia
